Literature DB >> 30502049

Relation of Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease to Left Ventricular Diastolic Function and Exercise Tolerance.

Justin McNair Canada1, Antonio Abbate2, Rebecca Collen3, Hayley Billingsley2, Leo Francis Buckley2, Salvatore Carbone2, Cory Ross Trankle2, Michael Ola Idowu4, Dinesh Kadariya2, Benjamin Van Tassell2, Arun Jayant Sanyal3, Mohammad Shadab Siddiqui3.   

Abstract

The purpose of this study was to determine the relation between liver histology, exercise tolerance, and diastolic function in patients with nonalcoholic fatty liver disease (NAFLD). Myocardial remodeling and diastolic dysfunction have been associated with NAFLD. However, its physiological impact and relationship to the histological severity of NAFLD is not known. Cardiopulmonary exercise testing and stress echocardiography was performed in subjects with biopsy-confirmed NAFLD. Maximal aerobic exercise capacity (peak oxygen consumption [VO2]) was related to diastolic function (mitral annulus Doppler velocity e' and ratio of early diastolic filling pressure [E] to e' [E/e']) at rest and peak exercise. Autonomic dysfunction was determined from heart rate recovery after exercise. Independent predictors of cardiac function and exercise capacity were identified by multivariable regression. Thirty-six subjects (nonalcoholic fatty liver [NAFL  =  15], nonalcoholic steatohepatitis [NASH  =  21]) were enrolled. NASH was associated with impaired exercise capacity compared with NAFL (median peak VO2 17.0 [15.4, 18.9] vs 19.9 [17.4, 26.0], p  =  001); pVO2 declined with increasing fibrosis (F0  =  22.5, F1  =  19.9, F2  =  19.0, F3  =  16.6 ml·kg-1·min-1; p  =  0.01). Similarly, E/e' during exercise increased progressively with increasing fibrosis (F0  =  5.6, F1  =  6.5, F2  =  8.7, F3  =  9.8; P  =  0.02). Finally, heart rate recovery, a marker of autonomic function, was blunted in those with higher fibrosis stages (F0  =  25 [20, 30], F1  =  23 [17.5, 27.0], F2  =  17 [11.8, 21.5], F3  =  11 [8.5, 18.0] beats per minute; p <0.01). Fibrosis was an independent predictor of these functional outcomes. In conclusion, NASH is associated with impaired exercise capacity and diastolic dysfunction compared with NAFL. The severity of impairment is directly related to the severity of fibrosis stage in precirrhotic stages of NAFLD.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2018        PMID: 30502049      PMCID: PMC6331258          DOI: 10.1016/j.amjcard.2018.10.027

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  29 in total

1.  ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging).

Authors:  Francis J Klocke; Michael G Baird; Beverly H Lorell; Timothy M Bateman; Joseph V Messer; Daniel S Berman; Patrick T O'Gara; Blase A Carabello; Richard O Russell; Manuel D Cerqueira; Martin G St John Sutton; Anthony N DeMaria; James E Udelson; J Ward Kennedy; Mario S Verani; Kim Allan Williams; Elliott M Antman; Sidney C Smith; Joseph S Alpert; Gabriel Gregoratos; Jeffrey L Anderson; Loren F Hiratzka; David P Faxon; Sharon Ann Hunt; Valentin Fuster; Alice K Jacobs; Raymond J Gibbons; Richard O Russell
Journal:  J Am Coll Cardiol       Date:  2003-10-01       Impact factor: 24.094

2.  Peak Exercise Oxygen Uptake Predicts Recurrent Admissions in Heart Failure With Preserved Ejection Fraction.

Authors:  Patricia Palau; Eloy Domínguez; Eduardo Núñez; José María Ramón; Laura López; Joana Melero; Juan Sanchis; Alejandro Bellver; Enrique Santas; Antoni Bayes-Genis; Francisco J Chorro; Julio Núñez
Journal:  Rev Esp Cardiol (Engl Ed)       Date:  2017-06-27

3.  2016 Focused Update: Clinical Recommendations for Cardiopulmonary Exercise Testing Data Assessment in Specific Patient Populations.

Authors:  Marco Guazzi; Ross Arena; Martin Halle; Massimo F Piepoli; Jonathan Myers; Carl J Lavie
Journal:  Circulation       Date:  2016-05-02       Impact factor: 29.690

4.  Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment.

Authors:  Sorel Goland; Sara Shimoni; Taiba Zornitzki; Hilla Knobler; Orly Azoulai; Gaby Lutaty; Ehud Melzer; Ayella Orr; Avraham Caspi; Stephen Malnick
Journal:  J Clin Gastroenterol       Date:  2006 Nov-Dec       Impact factor: 3.062

5.  Ectopic fat depots and left ventricular function in nondiabetic men with nonalcoholic fatty liver disease.

Authors:  Marit Granér; Kristofer Nyman; Reijo Siren; Markku O Pentikäinen; Jesper Lundbom; Antti Hakkarainen; Kirsi Lauerma; Nina Lundbom; Markku S Nieminen; Marja-Riitta Taskinen
Journal:  Circ Cardiovasc Imaging       Date:  2014-12-30       Impact factor: 7.792

6.  Prognostic value of cardiopulmonary exercise testing in heart failure with preserved ejection fraction. The Henry Ford HospITal CardioPulmonary EXercise Testing (FIT-CPX) project.

Authors:  Ali Shafiq; Clinton A Brawner; Heather A Aldred; Barry Lewis; Celeste T Williams; Christina Tita; John R Schairer; Jonathan K Ehrman; Mauricio Velez; Yelena Selektor; David E Lanfear; Steven J Keteyian
Journal:  Am Heart J       Date:  2016-01-12       Impact factor: 4.749

7.  Normalization for peak oxygen uptake increases the prognostic power of the ventilatory response to exercise in patients with chronic heart failure.

Authors:  Marco Guazzi; Stefano De Vita; Paola Cardano; Simona Barlera; Maurizio D Guazzi
Journal:  Am Heart J       Date:  2003-09       Impact factor: 4.749

8.  Vagally mediated heart rate recovery after exercise is accelerated in athletes but blunted in patients with chronic heart failure.

Authors:  K Imai; H Sato; M Hori; H Kusuoka; H Ozaki; H Yokoyama; H Takeda; M Inoue; T Kamada
Journal:  J Am Coll Cardiol       Date:  1994-11-15       Impact factor: 24.094

Review 9.  Heart Rate Recovery and Risk of Cardiovascular Events and All-Cause Mortality: A Meta-Analysis of Prospective Cohort Studies.

Authors:  Shanhu Qiu; Xue Cai; Zilin Sun; Ling Li; Martina Zuegel; Juergen Michael Steinacker; Uwe Schumann
Journal:  J Am Heart Assoc       Date:  2017-05-09       Impact factor: 5.501

10.  Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study.

Authors:  Lisa B VanWagner; Jane E Wilcox; Laura A Colangelo; Donald M Lloyd-Jones; J Jeffrey Carr; Joao A Lima; Cora E Lewis; Mary E Rinella; Sanjiv J Shah
Journal:  Hepatology       Date:  2015-06-26       Impact factor: 17.298

View more
  13 in total

Review 1.  Current management of non-alcoholic steatohepatitis.

Authors:  Mark D Muthiah; Arun J Sanyal
Journal:  Liver Int       Date:  2020-02       Impact factor: 5.828

2.  Non-Alcoholic Fatty Liver Disease Is Associated with Impairment of Ejection Fraction Among Individuals with Obesity Undergoing Bariatric Surgery: Results of a Cross-Sectional Study.

Authors:  Tiago Bezerra de Freitas Diniz; Rafael Nascimento de Jesus; Laísa Simakawa Jimenez; José Carlos Pareja; Elinton Adami Chaim; Everton Cazzo
Journal:  Obes Surg       Date:  2020-02       Impact factor: 4.129

Review 3.  Pathogenesis of non-alcoholic fatty liver disease and implications on cardiovascular outcomes in liver transplantation.

Authors:  Benedict J Maliakkal
Journal:  Transl Gastroenterol Hepatol       Date:  2020-07-05

4.  Prevalence and staging of non-alcoholic fatty liver disease among patients with heart failure with preserved ejection fraction.

Authors:  Alexandria Miller; Jennifer McNamara; Scott L Hummel; Matthew C Konerman; Monica A Tincopa
Journal:  Sci Rep       Date:  2020-07-24       Impact factor: 4.379

5.  Serial Biomarkers of De Novo Lipogenesis Fatty Acids and Incident Heart Failure in Older Adults: The Cardiovascular Health Study.

Authors:  Yujin Lee; Heidi T M Lai; Marcia C de Oliveira Otto; Rozenn N Lemaitre; Barbara McKnight; Irena B King; Xiaoling Song; Gordon S Huggins; Amanda R Vest; David S Siscovick; Dariush Mozaffarian
Journal:  J Am Heart Assoc       Date:  2020-02-05       Impact factor: 5.501

Review 6.  Lifestyle Interventions with a Focus on Nutritional Strategies to Increase Cardiorespiratory Fitness in Chronic Obstructive Pulmonary Disease, Heart Failure, Obesity, Sarcopenia, and Frailty.

Authors:  Hayley Billingsley; Paula Rodriguez-Miguelez; Marco Giuseppe Del Buono; Antonio Abbate; Carl J Lavie; Salvatore Carbone
Journal:  Nutrients       Date:  2019-11-21       Impact factor: 5.717

7.  The association between cardiorespiratory fitness, liver fat and insulin resistance in adults with or without type 2 diabetes: a cross sectional-analysis.

Authors:  Angelo Sabag; Shelley E Keating; Kimberley L Way; Rachelle N Sultana; Sean M Lanting; Stephen M Twigg; Nathan A Johnson
Journal:  BMC Sports Sci Med Rehabil       Date:  2021-04-16

Review 8.  Non-alcoholic fatty liver disease and heart failure with preserved ejection fraction: from pathophysiology to practical issues.

Authors:  Romain Itier; Maeva Guillaume; Jean-Etienne Ricci; François Roubille; Nicolas Delarche; François Picard; Michel Galinier; Jérôme Roncalli
Journal:  ESC Heart Fail       Date:  2021-02-03

9.  Pemafibrate suppresses NLRP3 inflammasome activation in the liver and heart in a novel mouse model of steatohepatitis-related cardiomyopathy.

Authors:  Kotaro Kanno; Masahiro Koseki; Jiuyang Chang; Ayami Saga; Hiroyasu Inui; Takeshi Okada; Katsunao Tanaka; Masumi Asaji; Yinghong Zhu; Seiko Ide; Shigeyoshi Saito; Tomoaki Higo; Daisuke Okuzaki; Tohru Ohama; Makoto Nishida; Yoshihiro Kamada; Masafumi Ono; Toshiji Saibara; Shizuya Yamashita; Yasushi Sakata
Journal:  Sci Rep       Date:  2022-02-22       Impact factor: 4.379

10.  Perceptions of Exercise and Its Challenges in Patients With Nonalcoholic Fatty Liver Disease: A Survey-Based Study.

Authors:  Oliver Glass; Daniel Liu; Elizabeth Bechard; Cynthia D Guy; Jane Pendergast; Anna Mae Diehl; Manal F Abdelmalek
Journal:  Hepatol Commun       Date:  2021-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.